The impact on insured groups is likely to be somewhat lower, and RGA believes it may be too early to make material adjustments to insured trend assumptions, but the efficacy of AOMs to date increases confidence in future mortality improvements
Safety Profile Retatrutide was tested in a safety profile and was mostly well-tolerated
Bjrn Pasternak, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined whether use of a GLP1 receptor agonist is associated with an increased risk for thyroid cancer in a Scandinavian cohort study in Denmark, Norway, and Sweden from 2007 to 2021
It is useful but not universally available and should be interpreted in clinical context
Some patients find that dietary modifications alone resolve symptoms without needing additional medications, making food adjustments the preferred first step
The result is higher absorption compared to standard forms